Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial
The study tested ivonescimab, an innovative bispecific antibody, combining it with platinum-doublet chemotherapy in patients whose lung cancer had a specific genetic mutation (EGFR) and whose cancer was...







